Behind KANJINTI®

IDENTICAL DOSING TO HERCEPTIN® IV

KANJINTI® PROVIDES IDENTICAL DOSING TO HERCEPTIN® IV ACROSS ALL INDICATIONS

Dosing similarity is one of several ways Amgen helps provide you and your patients with
a seamless experience.1,2

Adjuvant treatment, Breast Cancer
With paclitaxel or docetaxel
kanjinti dosing with paclitaxel or docetaxel for adjuvant treatment
With docetaxel and carboplatin
kanjinti dosing with docetaxel and carboplatin for adjuvant treatment
As single agent†
kanjinti dosing as single agent for adjuvant treatment
metastatic breast cancer
As Single Agent or with paclitaxel
kanjinti dosing as single agent or with paclitaxel for breast cancer
Metastatic Gastric Cancer
As Single Agent
kanjinti dosing as single agent or for gastric cancer
kanjinti dosing with paclitaxel or docetaxel for adjuvant treatment kanjinti dosing with docetaxel and carboplatin for adjuvant treatment kanjinti dosing as single agent for adjuvant treatment
kanjinti dosing as single agent or with paclitaxel for breast cancer
kanjinti dosing as single agent or for gastric cancer

IV = intravenous; QW = once a week; Q3W = once every 3 weeks.

Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines.

#1 Prescribed Trastuzumab Biosimilar
Available 150 mg and 420 mg vials KANJINTI® 150mg and 420 mg vials AMGEN has achieved zero supply shortages in the last decade

IV = intravenous; QW = once a week; Q3W = once every 3 weeks.

Please refer to accompanying full Prescribing Information for complete dosing and administration guidelines.

KANJINTI® has the same dosing as Herceptin® IV
across all indications1,2

*Within 3 weeks following completion lof all chemotherapy.

†EU-sourced Herceptin® was used in the LILAC study. The KANJINTI® clinical pharmacokinetic (PK) study demonstrated equivalence between EU- and US-sourced Herceptin® and KANJINTI®.

See how KANJINTI® is proven biosimilar to Herceptin®.‡

btn-medi_rainbow-svgtotality of evidence

*Current as of September 2022.

†Within 3 weeks following completion of all chemotherapy.

‡EU-sourced Herceptin® was used in the LILAC study. The KANJINTI® clinical pharmacokinetic (PK)
study demonstrated equivalence between EU- and US-sourced Herceptin® and KANJINTI®.